Quick Answer
Edgewise Therapeutics, Inc. reported R&D Expense of $151.39 million for fiscal year 2025.
Edgewise Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $151.39M | +19.2% |
| 2024 | $126.97M | +39.7% |
| 2023 | $90.91M | +68.2% |
| 2022 | $54.03M | +67.9% |
| 2021 | $32.19M | +114.8% |
| 2020 | $14.98M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $37.48M | +16.3% | +11.7% |
| June 30, 2025 | $33.56M | +9.4% | -8.7% |
| March 31, 2025 | $36.76M | +32.7% | +14.1% |
| September 30, 2024 | $32.22M | +35.5% | +5.0% |
| June 30, 2024 | $30.68M | +56.9% | +10.8% |
| March 31, 2024 | $27.69M | +39.3% | +16.4% |
| September 30, 2023 | $23.79M | +71.2% | +21.6% |
| June 30, 2023 | $19.56M | +57.7% | -1.6% |
- Edgewise Therapeutics, Inc. showed an increase of +19.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Edgewise Therapeutics, Inc.’s r&d expense has grown by 910.4% (from $14.98 million to $151.39 million).
- The most recent figure is from Edgewise Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: